Recent Updates
Recently added Catalysts
NVAX Positive Sentiment

Novavax to Host Conference Call to Discuss Second Quarter 2023 Financial Results and Operational Highlights on August 8, 2023

Key Takeaway: Novavax, Inc. has announced a conference call scheduled for August 8, 2023, to discuss its financial results for the second quarter of 2023 along with operational highlights. The call will begin at 8:30 a.m. EDT, and participants are encouraged to join early. Following the call, a replay will be available, providing further insights into the company's ongoing vaccine developments and financial performance.
Price reaction · baseline $9.28 (2023-07-31 close) · hit after-hours · clean, no other NVAX news in the window
day 0 close
-5.7%
day 1
-9.5%
day 3 · peak
-13.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Novavax is advancing protein-based vaccines with innovative technology.
  • The company is addressing significant health challenges through its vaccine developments.
  • Upcoming conference call may indicate positive financial performance.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~29 mo
Minimal dilution risk
Lead asset
SARS-CoV-2 rS/Matrix-M1 Adjuvant
Phase 3 · SARS-CoV-2 Infection

Full Press Release Details

GAITHERSBURG, Md., Aug. 1, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its second quarter 2023 financial results and operational highlights at 8:30 a.m. Eastern Daylight Time (EDT) on Tuesday, August 8, 2023. Details of the event and replay are as follows:
Conference call details:
Date: August 8, 2023
Time: 8:30 a.m. U.S. EDT
Dial-in number: (877) 883-0383 (Domestic) or (412) 902-6506 (International)
Passcode: 1209328
Webcast: ir.novavax.com/events
Participants will be prompted to request to join the Novavax, Inc. call.
To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
Replay details:
Date: Available starting at 11:30 a.m. EDT, August 8, 2023, until 11:59 p.m. U.S. EDT, August 15, 2023
Dial-in number: (877) 344-7529 (Domestic) or (412) 317-0088 (International)
Passcode: 2287018
Webcast: ir.novavax.com/events , until November 6, 2023
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID, influenza, and COVID and influenza combined. Please visit novavax.com and LinkedIn for more information.

Frequently Asked Questions

When will Novavax report its Q2 2023 financial results?

Novavax will report its second quarter 2023 financial results on August 8, 2023 at 8:30 a.m. EDT.

How can I join the Novavax conference call?

To join the Novavax call, dial (877) 883-0383 domestically or (412) 902-6506 internationally.

What is Novavax's focus in vaccine development?

Novavax focuses on developing vaccines for COVID, influenza, and their combination.

How long will the conference replay be available?

The conference replay will be available from August 8, 2023, 11:30 a.m. to August 15, 2023, 11:59 p.m. EDT.

What technology does Novavax use for its vaccines?

Novavax utilizes a recombinant protein platform combined with innovative nanoparticle technology.

Last updated: Aug 1, 2023